Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-28T20:26:05.004Z Has data issue: false hasContentIssue false
  • English
  • Français

Increase in Use of Vancomycin for Clostridium difficile Infection in US Hospitals

Published online by Cambridge University Press:  02 January 2015

Amy L. Pakyz ,
Norman V. Carroll ,
Spencer E. Harpe ,
Michael Oinonen  and
Ronald E. Polk
Amy L. Pakyz*
Affiliation:
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia
Norman V. Carroll
Affiliation:
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia
Spencer E. Harpe
Affiliation:
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia Department of Epidemiology and Community Health, School of Medicine, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia
Michael Oinonen
Affiliation:
University HealthSystem Consortium, Oak Brook, Illinois
Ronald E. Polk
Affiliation:
Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia
*
Virginia Commonwealth University School of Pharmacy, 410 North 12th Street, PO Box 980533, Richmond, VA 23298-0533 (apakyz@vcu.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Clostridium difficile infection (CDI) is a potentially serious disease for which the epidemiology has recently changed, because of an emerging drug-resistant strain of the pathogen. Metronidazole and oral vancomycin are the primary treatment agents.2 Metronidazole has been historically favored as the first-line agent, partly to reduce the selection pressure for vancomycin-resistant enterococci (VRE), although metronidazole can also select for VRE. Vancomycin was traditionally reserved for metronidazole treatment failure or life-threatening disease. In a study conducted before emergence of the epidemic strain, vancomycin was reported to be superior for the initial treatment of severe CDI and for treatment of CDI that does not respond to metronidazole. Expert opinion calling for the use of vancomycin as first-line therapy, especially for severe CDI emergence of the epidemic strain, and reports of decreased metronidazole efficacy may have impacted CDI treatment practices. The purpose of this study was to characterize trends in CDI treatment in US hospitals.

Type
Research Briefs
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue 8 , August 2010 , pp. 867 - 868
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.McDonald, LC, Killgore, GE, Thompson, A, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.CrossRefGoogle ScholarPubMed
2.Bartlett, JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008;46:1489–1492.Google Scholar
3.Gerding, DN, Johnson, S, Peterson, Jr, Mulligan, ME, Silva, J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459–477.Google Scholar
4.Al-Nassir, WA, Sethi, AK, Li, Y, Pultz, MJ, Riggs, MM, Donskey, CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403–2406.Google Scholar
5.Zar, FA, Bakkanagari, SR, Moorthi, KM, Davis, MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.Google Scholar
6.Pepin, J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008;46:1493–1498.Google Scholar
7.Musher, DM, Aslam, S, Logan, N, et al.Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–1590.Google Scholar
8.Schmiedeskamp, M, Harpe, SE, Polk, RE, Oinonen, M, Pakyz, AL. Using International Classification of Diseases, 9th Edition, Clinical Modification codes and drug utilization data to identify hospital acquired Clostridium difficile infection. Infect Control Hosp Epidemiol 2009;30:1070–1076.Google Scholar